PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
Muñoz-Gámez
José Antonio
JA
Hospital Universitario San Cecilio, Granada, Spain.
Martín-Oliva
David
D
Aguilar-Quesada
Rocío
R
Cañuelo
Ana
A
Nuñez
M Isabel
MI
Valenzuela
M Teresa
MT
Ruiz de Almodóvar
J M
JM
De Murcia
Gilbert
G
Oliver
F Javier
FJ
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D053148:Caspase 3; D020169:Caspases / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004357:Drug Synergism; D005260:Female; D016158:Genes, p53; D006801:Humans; D007425:Intracellular Membranes / Q000187:drug effects; D008564:Membrane Potentials / Q000187:drug effects; D008928:Mitochondria / Q000187:drug effects; D053644:Naphthalimides; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000071137:Poly (ADP-Ribose) Polymerase-1; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D015363:Quinolones / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D014410:Tumor Stem Cell Assay; D016159:Tumor Suppressor Protein p53 / Q000172:deficiency*; D051028:bcl-2-Associated X Protein
C494826:BAX protein, human; D053644:Naphthalimides; D009363:Neoplasm Proteins; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D015363:Quinolones; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein; C086538:4-amino-1,8-naphthalimide; D004317:Doxorubicin; D015057:1-Naphthylamine; C499320:PARP1 protein, human; D000071137:Poly (ADP-Ribose) Polymerase-1; D011065:Poly(ADP-ribose) Polymerases; C505407:CASP3 protein, human; D053148:Caspase 3; D020169:Caspases